Stifel Nicolaus Issues Pessimistic Forecast for Cipher Pharmaceuticals (TSE:CPH) Stock Price

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its price objective trimmed by Stifel Nicolaus from C$19.00 to C$17.00 in a report published on Monday morning,BayStreet.CA reports.

CPH has been the subject of a number of other research reports. Stifel Canada upgraded shares of Cipher Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 12th. Leede Financial lowered shares of Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 13th.

Cipher Pharmaceuticals Stock Performance

CPH opened at C$12.71 on Monday. The firm has a market cap of C$325.25 million, a P/E ratio of 10.17 and a beta of 1.20. Cipher Pharmaceuticals has a 1-year low of C$5.31 and a 1-year high of C$19.69. The company has a 50 day simple moving average of C$15.84 and a two-hundred day simple moving average of C$12.36. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings results on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.03 by C($0.02). The firm had revenue of C$14.15 million during the quarter, compared to the consensus estimate of C$13.37 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. Equities analysts forecast that Cipher Pharmaceuticals will post 1.2907348 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.